<DOC>
	<DOC>NCT01591668</DOC>
	<brief_summary>Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules. Subjects will be confined on either days 1-3 and/or days 8-10. Follow-up visits are also required periodically through day 43. Study procedures involve taking blood samples for pharmacokinetic, pharmacodynamic, virologic, and safety assessments.</brief_summary>
	<brief_title>A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Males and Females 1865 years old Chronic HCV infection for at least 6 months, treatment naive HCV Viral load &gt; 100,000 IU/mL at Screening Monoinfection with HCV 1 genotype Hepatitis B surface antigen negative Screening ECG without clinically significant abnormalities BMI 1833 kg/m^2 Creatinine clearing &gt; 70 mL/min Negative pregnancy test at screening Pregnant or lactating subjects Coinfection with hepatitis B virus (HBV) or HIV History of Gilberts disease Particular abnormal laboratory parameters Diagnosis of autoimmune disease, poorly controlled diabetes, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), malignancy, hemoglobinopathy, retinal disease, and those who are immunosuppressed Evidence of hepatocellular carcinoma Ongoing alcohol abuse Positive uring drug screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Chronic HCV</keyword>
	<keyword>HCV</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Gilead</keyword>
	<keyword>GS-9620</keyword>
</DOC>